ide-161
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Apr 5, 2023 (NCT05787587)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Breast Neoplasms · Phase 1
- Carcinoma, Non-Small-Cell Lung · Phase 1
- Colorectal Neoplasms · Phase 1
- Endometrial Neoplasms · Phase 1
- Lung Neoplasms · Phase 1
- Neoplasms · Phase 1
- Ovarian Neoplasms · Phase 1
- Pancreatic Neoplasms · Phase 1
- Prostatic Neoplasms · Phase 1
- Squamous Cell Carcinoma of Head and Neck · Phase 1
Mechanism of action
- Poly(ADP-ribose) glycohydrolaseINHIBITOR
PARG inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05787587 | Phase 1 | Apr 5, 2023 | IDEAYA Biosciences |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| IDEAYA Biosciences | For profit | 1 | 1 | 1 | 2023 |
1 organizations
Page 1 / 1